Poxel S.A. (FRA:7PO)

Market Cap	12.47M
Revenue (ttm)	6.64M
Net Income (ttm)	-18.31M
Shares Out	n/a
EPS (ttm)	-0.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	400
Open	0.2315
Previous Close	0.2330
Day's Range	0.2315 - 0.2315
52-Week Range	0.0010 - 0.8030
Beta	n/a
RSI	39.86
Earnings Date	Mar 23, 2026

About Poxel

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatoh...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 6
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7PO

Financial Performance

In 2024, Poxel's revenue was 6.64 million, an increase of 234.98% compared to the previous year's 1.98 million. Losses were -18.31 million, -47.83% less than in 2023.